Plain-English translation of NCT06683391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The REMODAL trial is testing three different approaches to treating mild low blood sugar in people with type 1 diabetes who use continuous glucose monitoring devices. Instead of following outdated guidelines from the 1980s, this study compares whether treating low blood sugar earlier with smaller amounts of carbohydrates works better than waiting until blood sugar drops very low and using larger amounts. The goal is to find personalized approaches that help people prevent serious low blood sugar episodes while avoiding the swings that come after treatment.
Current guidelines for treating low blood sugar haven't been updated since the 1980s, even though insulin therapies and glucose monitoring technology have improved dramatically. This study exists to figure out whether we can prevent low blood sugar more effectively by treating it earlier and with different amounts of carbohydrates, which could improve quality of life and reduce scary episodes.
You likely qualify if…
You likely don't qualify if…
You would use your continuous glucose monitor as usual, but follow one of three specific carbohydrate treatment approaches for low blood sugar episodes. The three approaches test different amounts of carbohydrates (8 or 16 grams) given at different blood sugar thresholds (when your glucose is at 5.0 or below 4.0). The study tracks how well each approach prevents low blood sugar, manages your overall glucose levels, and avoids high blood sugar swings afterward.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Canada